Five-Year Check-Up for rare growth disorder drug
NCT ID NCT04980833
Summary
This study is following patients with a rare genetic overgrowth condition (PROS) who are already taking the drug alpelisib. It aims to monitor the long-term safety and effectiveness of the medication over five years. The study is only for people who were in a previous clinical trial for this drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Childrens Hospital
Boston, Massachusetts, 02215, United States
-
Novartis Investigative Site
Dijon, 21000, France
-
Novartis Investigative Site
Montpellier, 34295, France
-
Novartis Investigative Site
Paris, 75015, France
-
Novartis Investigative Site
Dublin, 12, Ireland
-
Novartis Investigative Site
Madrid, 28046, Spain
Conditions
Explore the condition pages connected to this study.